P Ozdinler H, Gautam M, Gozutok O, Konrad C, Manfredi G, Gomez EArea, Mitsumoto H, Erb ML, Tian Z, Haase G.
2020.
Better understanding the neurobiology of primary lateral sclerosis.. Amyotroph Lateral Scler Frontotemporal Degener. 21(sup1):35-46.
Stepanova A, Shurubor Y, Valsecchi F, Manfredi G, Galkin A.
2016.
Differential susceptibility of mitochondrial complex II to inhibition by oxaloacetate in brain and heart.. Biochim Biophys Acta. 1857(9):1561-8.
Konrad C, Kawamata H, Bredvik KG, Arreguin AJ, Cajamarca SA, Hupf JC, Ravits JM, Miller TM, Maragakis NJ, Hales CM et al..
2017.
Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients.. Mol Neurodegener. 12(1):76.
Nelson AT, Cicardi MElena, Markandaiah SS, Han JYs, Philp NJ, Welebob E, Haeusler AR, Pasinelli P, Manfredi G, Kawamata H et al..
2024.
Glucose hypometabolism prompts RAN translation and exacerbates C9orf72-related ALS/FTD phenotypes.. EMBO Rep. 25(5):2479-2510.
Yang S, Le Kernec J, Romain O, Fioranelli F, Cadart P, Fix J, Ren C, Manfredi G, Letertre T, Saenz IDavid Hino et al..
2023.
The Human Activity Radar Challenge: benchmarking based on the 'Radar signatures of human activities' dataset from Glasgow University.. IEEE J Biomed Health Inform. PP
Woo E, Bredvik K, Liu B, Fuchs TJ, Manfredi G, Konrad C.
2023.
Machine learning approaches based on fibroblast morphometry do not predict ALS.. Neurobiol Aging. 130:80-83.
Kawamata H, Peixoto P, Konrad C, Palomo G, Bredvik K, Gerges M, Valsecchi F, Petrucelli L, Ravits JM, Starkov A et al..
2017.
Mutant TDP-43 does not impair mitochondrial bioenergetics in vitro and in vivo.. Mol Neurodegener. 12(1):37.